Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug prolongs lives of chronic lymphocytic leukemia patients

08.12.2003


The drug rituximab significantly prolonged the lives of some people with chronic lymphocytic leukemia (CLL), the most common form of leukemia in adult Americans.

The findings come from a comparative analysis of two completed national phase II and phase III clinical trials that will be presented Dec. 8, 8:00 a.m. PT, at the 45th annual meeting of the American Society of Hematology (ASH) in San Diego, Calif.

The two multicenter clinical trials compare the antibody rituximab plus fludarabine, a chemotherapeutic drug, to fludarabine alone. Rituximab is an antibody-based drug approved for lymphoma. Physicians now use fludarabine alone as the current standard therapy for CLL.



The findings of the two studies show that after an average of 43 months, rituximab plus the drug fludarabine increases progression-free survival by 22 percent and overall survival by 12 percent compared to fludarabine alone.

“The findings are the first of any tested modern therapy to show a significant improvement in overall survival for people with CLL,” says study leader John C. Byrd, a medical oncologist with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Byrd will present the findings at ASH.

“The results suggest that rituximab is going to be an extremely important drug in the treatment of this disease.”

An estimated 7,300 Americans will be diagnosed with CLL in 2003, and 4,400 people are expected to die of the disease. The disease causes no symptoms initially. Doctors usually diagnose it through routine blood tests; average age at diagnosis is 62. Early stage patients can live 10 years or more, but patients with more advanced disease may live only 18 months to three years.

Rituximab is a monoclonal antibody that targets a protein known as CD20 found on immune cells known as B lymphocytes. Scientists believe rituximab kills malignant CLL cells by causing programmed cell death, or apoptosis.

This randomized phase 2 study included 104 previously untreated CLL patients. The outcomes of these patients were compared to those of 179 similar patients who received fludarabine alone as part of an earlier randomized trial.

The earlier trial, known as Cancer and Leukemia Group B (CALGB) 9011, compared fludarabine alone to the drug chlorambucil, the former standard of care for CLL. The results of that study (published in the Dec. 14, 2000, New England Journal of Medicine) established fludarabine alone as the standard of care in CLL patients.

Of patients receiving fludarabine alone in that study, 81 percent had survived after two years, 20 percent experienced a complete remission and 45 percent showed no progression of their disease.

Of patients receiving rituximab plus fludarabine in this new study (known as CALGB 9712), 93 percent had survived after two years, 38 percent experienced a complete remission and 67 percent showed no disease progression.

“That’s a significant improvement,” says Byrd, the D. Warren Brown Professor in Leukemia Research, and a Leukemia and Lymphoma Society of America Clinical Scholar.

The findings also may cause investigators to re-think the best time to begin therapy for CLL in patients with a high likelihood of developing progressive disease. Older studies showed that giving patients chlorambucil early did not improve survival, so doctors don’t usually begin therapy until symptoms appear.

“This study may cause us to re-evaluate that approach,” Byrd says. “Future clinical trials may test whether giving rituximab alone or in combination when the disease is just diagnosed is beneficial.”

Funds from the National Cancer Institute, Kimmel Cancer Research Foundation, the Leukemia and Lymphoma Society of America and D. Warren Brown Foundation supported this research

The CALGB is a national clinical research group sponsored by the National Cancer Institute and founded in 1955 to improve cancer treatment, prevention and detection. The group consists of nearly 30 university medical centers, over 185 community hospitals and almost 3000 collaborating physicians and focuses on leukemia, lymphoma, melanoma and cancers of the breast, lung, gastrointestinal tract and genito-urinary tract.



Contact: Darrell E. Ward, (614) 293-3737; Ward-15@medctr.osu.edu

Darrell E. Ward | Ohio State University
Further information:
http://researchnews.osu.edu/archive/rituxim.htm

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Water cooling for the Earth's crust

23.11.2017 | Earth Sciences

Nano-watch has steady hands

23.11.2017 | Physics and Astronomy

Batteries with better performance and improved safety

23.11.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>